Coronavirus vaccines in India: When the nation faced a shortage of vaccine provide last month, the government had mentioned that it would procure more than 200 crore vaccine doses in the period involving April and December this year. These numerous doses would be adequate to inoculate the complete adult population of India. Accordingly, the new vaccine policy states the Centre’s program to procure 75 crore doses of SII’s Covishield and 55 crore doses of Bharat Biotech’s Covaxin, as these are the two vaccines getting made use of in the nation for the coronavirus vaccination drive. The remaining doses would either be procured from foreign companies or would involve procuring doses of these indigenous vaccines that are presently in their sophisticated stage of trials.
Here’s a look at all the vaccines that are upcoming in India:
Covovax: The vaccine created by American biotech firm Novavax has shown to be 90.4% powerful in its late-stage trials, and so accordingly, Serum Institute of India (SII) — which would be creating and supplying the vaccine beneath the name Covovax in India — could start with the protein-based vaccine’s trials on children next month. The trials of the vaccine have been carried out in the US and Mexico, and post the announcement of outcomes, India’s COVID-19 Task Force member Dr VK Paul urged SII to start the clinical trials in India as quickly as probable. In truth, the vaccine’s bridging study in India is currently in its sophisticated stage of completion, and for that reason, he had mentioned that the paediatric trials of the vaccine could start now. It is anticipated that India would procure 20 crore doses of the vaccine involving August and December.
Catch live updates on coronavirus right here
Biological E’s Corbevax: Hyderabad-based manufacturer Biological E has currently received an sophisticated payment of Rs 1,500 crore from the Centre in order to pre-book 30 crore doses of its Corbevax vaccine, which is nevertheless getting created. This payment marked the very first instance of the Indian government putting an order of doses with the manufacturer prior to the vaccine has been authorized for emergency use by the regulatory authorities. Corbevax, which showed promising outcomes in its very first and second phase trials, is presently beneath the third trial phase. If the Centre’s program is to be believed, the manufacturer would make 30 crore doses of the vaccine involving August and December, and of these, 7.5 crore doses would be supplied by September.
ZyCov-D: Zydus Cadila based in Ahmedabad is manufacturing a vaccine referred to as ZyCov-D, which is in its third phase of clinical trials. The manufacturer is anticipated to apply for emergency use authorisation for the vaccine sometime quickly. The business is anticipated to make about 5 crore doses of the vaccine involving August and December this year, and after it applies for the licence, the government would know whether or not it would be match for administration amongst children or not.
Sputnik V booster shot: While Russian vaccine Sputnik V has been authorised for use in India and it is currently getting administered in the nation. However, now, the vaccine developer Gamaleya Research Institute of Epidemiology and Microbiology has mentioned that it would quickly be launching a booster shot version of the vaccine that would target the Delta variant of SARS-CoV-2, and this would be made out there to other companies as nicely. However, no other information concerning efficacy or timeline have been shared by Russia but in this regard.
Gennova’s HGCO19: Gennova Biopharma situated in Pune is presently in the very first phase of the clinical trial of its coronavirus vaccine HGCO19. The firm had gotten the go-ahead from DCGI for the very first phase of the vaccine trials in December last year, but they got delayed when the vaccine had to undergo an animal toxicity study once more on the directions of the regulator.
Nasal shot vaccine: Being created by Hyderabad-based Bharat Biotech in collaboration with Washington University School of Medicine, the intranasal vaccine for coronavirus is presently in phase 1-2 clinical trial. Named BBV154, it is aimed to be a single-dose vaccine that could overcome the problems concerning the delivery and administration of injectable vaccines. Moreover, it is most likely that the vaccine could also immunise the cells in tissues that are present in the nose, the mouth and the lungs of the person. The government has stated in the previous that soon after the conclusion of the trials, 10 crore doses of the nasal vaccine would be supplied by Bharat Biotech.